FDA-cleared profile

vascuCAP

Elucid Bioimaging Inc. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: vascuCAP analyzes contrast multidetector CT of arterial vessels to support atherosclerosis stratification with color maps, three-dimensional views, multiplanar reformats, and measurements for physician review.

Clinical role
Medical-image processing, measurement, quantification, visualization, and reporting support.
Images and patients
CT/CTA · Heart/Cardiovascular
Key limitation
Keep in mind: The measurements provided by vascuCAP are not intended to provide a diagnosis or clinical recommendations. vascuCAP is intended as a tool to complement standard of care. Stenosis by diameter may be overestimated when the lumen becomes appreciably smaller than the finite voxel size; quantitative calculations should be disregarded when the lumen is not readily visualized and judged qualitatively.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: vascuCAP analyzes contrast multidetector CT of arterial vessels to support atherosclerosis stratification with color maps, three-dimensional views, multiplanar reformats, and measurements for physician review.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Heart/Cardiovascular Input: Multi-dimensional digital images acquired with contrast from CT imaging devices, including images obtained using a multidetector CT.
  • Who uses it?Intended users: Trained physicians.
  • What does the software produce?Output: Measurement and visualization using color-coded maps of arterial vessels, including a highlighted vessel in 3D, rotatable curved MPR vessel views, vessel cross sections, lumen boundaries, stenosis measurements, maximum and minimum lumen diameters, Hounsfield unit or signal intensity statistics, and vessel length along the centerline.
  • What is its most important limitation?Key limitation: The measurements provided by vascuCAP are not intended to provide a diagnosis or clinical recommendations. vascuCAP is intended as a tool to complement standard of care. Stenosis by diameter may be overestimated when the lumen becomes appreciably smaller than the finite voxel size; quantitative calculations should be disregarded when the lumen is not readily visualized and judged qualitatively.

Clinical takeaway. Clinical role: vascuCAP analyzes contrast multidetector CT of arterial vessels to support atherosclerosis stratification with color maps, three-dimensional views, multiplanar reformats, and measurements for physician review.

Evidence takeaway. Evidence from the reviewed source record: K183012 reports software, measurement, visualization, and clinical testing for arterial CT analysis. Measurements are not intended to establish a diagnosis or clinical recommendation and complement standard of care; the public FDA summary does not provide a reliable single sensitivity or specificity value.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
vascuCAP analyzes contrast multidetector CT of arterial vessels to support atherosclerosis stratification with color maps, three-dimensional views, multiplanar reformats, and measurements for physician review.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.

Workflow role
Medical-image processing, measurement, quantification, visualization, and reporting support.
  • Exact FDA submission
  • Checked 2026-09-03
Required input
Multi-dimensional digital images acquired with contrast from CT imaging devices, including images obtained using a multidetector CT.
  • Exact FDA submission
  • Checked 2026-09-19

The exact indication and device description define the contrast-enhanced CT image input.

Output and clinician action
Measurement and visualization using color-coded maps of arterial vessels, including a highlighted vessel in 3D, rotatable curved MPR vessel views, vessel cross sections, lumen boundaries, stenosis measurements, maximum and minimum lumen diameters, Hounsfield unit or signal intensity statistics, and vessel length along the centerline.
  • Exact FDA submission
  • Checked 2026-09-19

The exact indication lists the supported vessel visualization and measurement functions; unsupported segmentation and report claims are removed.

Care setting
Hospital or outpatient imaging analysis and reporting environments.
  • Exact FDA submission
  • Checked 2026-09-03
Intended users
Trained physicians.
  • Exact FDA submission
  • Checked 2026-09-19

The exact indication states that vascuCAP is intended to assist trained physicians.

Limitations
The measurements provided by vascuCAP are not intended to provide a diagnosis or clinical recommendations. vascuCAP is intended as a tool to complement standard of care. Stenosis by diameter may be overestimated when the lumen becomes appreciably smaller than the finite voxel size; quantitative calculations should be disregarded when the lumen is not readily visualized and judged qualitatively.
  • Exact FDA submission
  • Checked 2026-09-19

The exact indications and performance discussion state the diagnostic boundary, standard-of-care role, and stenosis-by-diameter caveat.

Evidence summary
K183012 reports software, measurement, visualization, and clinical testing for arterial CT analysis. Measurements are not intended to establish a diagnosis or clinical recommendation and complement standard of care; the public FDA summary does not provide a reliable single sensitivity or specificity value.
  • Exact FDA submission
  • Checked 2026-09-03

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K183012 reports software, measurement, visualization, and clinical testing for arterial CT analysis. Measurements are not intended to establish a diagnosis or clinical recommendation and complement standard of care; the public FDA summary does not provide a reliable single sensitivity or specificity value.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-03
Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Sensitivity is not the primary endpoint for this system, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Specificity is not the primary endpoint for this system, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K183012 FDA performance package for vascuCAP

  • DesignManufacturer analytical, software, measurement, visualization, and clinical validation
  • PopulationContrast multidetector CT examinations of arterial vessels for atherosclerosis stratification
  • Scopeexact submission
  • Tested versionvascuCAP
  • IndependenceSponsor or vendor study

K183012

Manufacturer evidence submitted for FDA clearance or approval; local clinical, technical, and workflow acceptance remains necessary.

5 unlinked candidate evidence records are retained for source review and excluded from this evidence display.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K183012 by exact submission identifier. This does not exclude product-family, later, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-03

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance or approval.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Multi-dimensional digital images acquired with contrast from CT imaging devices, including images obtained using a multidetector CT.

    Scope: Exact FDA submission. The exact indication and device description define the contrast-enhanced CT image input.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K183012: vascuCAP

  2. Routing

    Source context, not route validation: DICOM import and output to PACS, reporting, or downstream systems; validate identifiers, series selection, measurements, units, geometry, routing, and round trips.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-03 · FDA K183012: vascuCAP

  3. AI processing

    Source context, not route validation: Software on a workstation, server, or supported virtual environment with release-specific licenses.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-03 · FDA K183012: vascuCAP

  4. Returned objects

    Source context, not route validation: Measurement and visualization using color-coded maps of arterial vessels, including a highlighted vessel in 3D, rotatable curved MPR vessel views, vessel cross sections, lumen boundaries, stenosis measurements, maximum and minimum lumen diameters, Hounsfield unit or signal intensity statistics, and vessel length along the centerline.

    Scope: Exact FDA submission. The exact indication lists the supported vessel visualization and measurement functions; unsupported segmentation and report claims are removed.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K183012: vascuCAP

  5. Viewer/worklist/report

    Unresolved route: Measurement and visualization using color-coded maps of arterial vessels, including a highlighted vessel in 3D, rotatable curved MPR vessel views, vessel cross sections, lumen boundaries, stenosis measurements, maximum and minimum lumen diameters, Hounsfield unit or signal intensity statistics, and vessel length along the centerline.

    Scope: Exact FDA submission. The exact indication lists the supported vessel visualization and measurement functions; unsupported segmentation and report claims are removed.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K183012: vascuCAP

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Software on a workstation, server, or supported virtual environment with release-specific licenses.
  • Exact FDA submission
  • Checked 2026-09-03
Integration
DICOM import and output to PACS, reporting, or downstream systems; validate identifiers, series selection, measurements, units, geometry, routing, and round trips.
  • Exact FDA submission
  • Checked 2026-09-03
Training
Only qualified imaging professionals and physicians trained for the represented anatomy and workflow should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-03
Monitoring
Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Measurements and maps are adjunctive and are not intended to make a diagnosis or clinical recommendation. Verify contrast timing, arterial coverage, reconstruction, manual edits, and the exact validated vessel set locally.
  • Exact FDA submission
  • Checked 2026-09-03

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, outputs, and enabled AI functions to K183012 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

DICOM import and output to PACS, reporting, or downstream systems; validate identifiers, series selection, measurements, units, geometry, routing, and round trips.

exact submission · checked 2026-09-03

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally. The capability is derived from the exact FDA workflow and still requires local acceptance testing.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Measurements and maps are adjunctive and are not intended to make a diagnosis or clinical recommendation. Verify contrast timing, arterial coverage, reconstruction, manual edits, and the exact validated vessel set locally.

exact submission · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-03

No exact-product price was found in the reviewed public material; vendor productivity claims are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Measurements and maps are adjunctive and are not intended to make a diagnosis or clinical recommendation. Verify contrast timing, arterial coverage, reconstruction, manual edits, and the exact validated vessel set locally.

exact submission · checked 2026-09-03

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. The capability is derived from the exact FDA workflow and still requires local acceptance testing.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K183012
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

The exact indication states that images are acquired with contrast from CT imaging devices and post-processed from multidetector CT. Controlled directory display reconciled from exact FDA wording: Contrast-enhanced multidetector CT. -> CT/CTA.

Anatomy
Heart/Cardiovascular
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

The exact indication identifies arterial vessels as the represented anatomy and does not establish the dossier's heart/cardiovascular label. Controlled directory display reconciled from exact FDA wording: Arterial vessels. -> Heart/Cardiovascular.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2018-12-21
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
28Fields reviewed
13Source classes checked
5Screened PubMed leads
3Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 5 PubMed and 3 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 5 PubMed and 3 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, fda decision summary packet, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-03 - Exact FDA submission

    Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.

  • Installation timeline: Not yet reviewed

14 sources - 3 history items

Source ledger

  1. FDA K183012: vascuCAP

    U.S. Food and Drug Administration - Published 2018-12-21 - Accessed 2026-09-19

    Scope: purpose, modality, anatomy, intendedUsers, input, output, limitations, evidenceSummary, clinicalUse

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Intra- and inter-reader reproducibility in quantitative coronary plaque analysis on coronary computed tomography angiography.

    U.S. National Library of Medicine - Accessed 2026-09-03

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  8. Treatment of Psoriasis With Biologic Therapy Is Associated With Improvement of Coronary Artery Plaque Lipid-Rich Necrotic Core: Results From a Prospective, Observational Study.

    U.S. National Library of Medicine - Accessed 2026-09-03

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  9. A Propensity-Matched Comparison of Ischemic Brain Lesions on Postprocedural MRI in Endovascular versus Open Carotid Artery Reconstruction.

    U.S. National Library of Medicine - Accessed 2026-09-03

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  10. Carotid plaque CTA analysis in patients with initial and recurrent ischemic stroke.

    U.S. National Library of Medicine - Accessed 2026-09-03

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  11. Semiautomated carotid artery plaque composition: are intraplaque CT imaging features associated with cardiovascular risk factors?

    U.S. National Library of Medicine - Accessed 2026-09-03

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  12. Non-invasive Computer-Aided Phenotyping of Vasculopathy

    U.S. National Library of Medicine - Accessed 2026-09-03

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  13. Carotid Risk Prediction (CRISP) Consortium

    U.S. National Library of Medicine - Accessed 2026-09-03

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  14. Plaque Stratification Using Ccta in Coronary ARtery Disease (PoSTCARD)

    U.S. National Library of Medicine - Accessed 2026-09-03

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

Research history

  1. K183012 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K251027

cvi42 Coronary Plaque Software Application

Circle Cardiovascular Imaging, Inc.

Authorized purpose: cvi42 Coronary Plaque supports qualified professionals with viewing, post-processing, and qualitative and quantitative evaluation of adult cardiac CT DICOM images to assess the presence and extent of coronary plaques and stenoses in CCTA for CAD or suspected CAD.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-10-27
FDA-cleared K243229

Bunkerhill AVC

BunkerHill Health

Authorized purpose: Adjunctive opportunistic detection and quantification of aortic valve calcification during routine clinical-care chest CT review; a physician reviews the informational ROI and estimated calcium burden and decides any further action.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-01-27
FDA-cleared K252217

CT VScore+

Canon Medical Informatics, Inc.

Authorized purpose: CT VScore+ evaluates calcified coronary lesions on ECG-gated, non-contrast cardiac CT in patients aged 30 years or older, automatically generating coronary calcium scores and highlighted calcium segmentation for qualified clinical review.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-11-28

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history